April 26 (Reuters) - Abbott Laboratories ABT.N:
NEW CLINICAL STUDY DATA SHOWCASE LONG-TERM, SUSTAINED BENEFITS OF ABBOTT'S VOLT™ PFA SYSTEM FOR PATIENTS WITH AFIB
ABBOTT LABORATORIES - VOLT PFA SYSTEM SHOWS STRONG 12-MONTH RESULTS
ABBOTT LABORATORIES - 83.5% PAF AND 58.1% PERSAF PATIENTS ARRHYTHMIA-FREE AFTER 12 MONTHS
ABBOTT LABORATORIES - ONLY 2.7% EXPERIENCED SAFETY ENDPOINT EVENT AFTER 12 MONTHS
Source text: ID:nPn4QqGp1a
Further company coverage: ABT.N
((Reuters.Briefs@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。